on behalf of the Northern New England Cardiovascular Disease Study Background-The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial was designed to compare optimal medical therapy alone versus optimal medical therapy and percutaneous coronary intervention (PCI) for treatment of patients with stable coronary artery disease and showed equal efficacy for optimal medical therapy with or without PCI. The impact of results from the COURAGE trial on clinical practice is unknown. Methods and Results-We analyzed 26 388 consecutive patients from the Northern New England Cardiovascular Disease PCI Registry who underwent PCI between January 2006 and June 2009. We identified a COURAGE-like patient group as patients who were undergoing (1) an elective procedure;
I n the last decade, advances in medical and percutaneous treatment for ischemic heart disease have come with considerable debate about defining optimal treatment. Given the prevalence and economic burden of cardiovascular diseases on the US population, 1 results from major cardiovascular trials receive intense news media coverage; influence evidence-based guideline recommendations, and may shape clinical practice.
Patients with chronic stable angina represent an important subset of patients with ischemic heart disease. It is estimated that in the United States alone, more than 16 million people may have chronic stable angina, 1 and current guidelines recommend initial optimization of medical therapy to im-prove quality and quantity of life. 2 Revascularization with either coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) is reserved for those who are refractory to medical therapy or exhibit high-risk clinical or anatomic features. [3] [4] [5] [6] [7] [8] [9] 
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More recently, the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) compared optimal medical treatment alone with optimal medical treatment plus PCI for patients with stable coronary artery disease (CAD). Trial results showed equal rates of death and myocardial infarction for medical therapy with or without PCI. This trial was presented at the American College of Cardiology meeting in March of 2007, published on April 12, 2007 , and received immediate and intense media coverage questioning the need for "routine" PCI for patients with chronic stable CAD. 10, 11 Studies of the affect of randomized trials on real-world practice have reported variable results. 12, 13 The impact of results from the COURAGE trial and the widespread media coverage on clinician behavior has not been determined. Accordingly, we sought to evaluate trends in practice among all patients enrolled in the Northern New England Cardiovascular Study Group PCI registry before and after release of COURAGE to assess the impact of COURAGE on clinical practice among patients with chronic stable angina and CAD.
WHAT IS KNOWN
• Patients with stable angina represent an important subset of patients with ischemic heart disease. • The COURAGE trial demonstrated equivalent outcomes in stable ischemic heart disease between PCI plus optimal medical therapy and optimal medical therapy alone for the outcomes of death and myocardial infarction. • The impact of COURAGE results on subsequent clinical practice is not known.
WHAT THE STUDY ADDS
• Practice of PCI for stable angina has regional variations. • In northern New England, there was a significant and sustained decrease in PCI among patients with stable angina as compared with unstable coronary syndromes after the publication of COURAGE. • Results of major trials and resultant media coverage can have substantial impact on clinical practice.
Methods

Data
Data were obtained from the PCI registry of the Northern New England Cardiovascular Disease Study Group (NNE). The NNE is a voluntary research consortium composed of clinicians, research scientists, and hospital administrators at 10 institutions in NNE that perform coronary revascularization. The goal of the group is to foster continuous improvement in the quality, safety, and effectiveness of care for patients with cardiovascular disease through the analysis of process and outcomes data with timely feedback to the health care professionals providing these services. The NNE PCI Registry contains data on consecutive procedures, including information on demographics, comorbidities, medical history, cardiac history, coronary anatomy and function, medical therapy, procedural priority, indication and process, and in-hospital outcomes as previously described. 14 To ensure there are data for all PCI patients, the clinical registry is validated by comparison to an administrative dataset.
Cohorts
We identified the COURAGE-like patient group in the NNE PCI Registry as patients who were undergoing (1) an elective procedure;
(2) for an indication of stable angina; and (3) on the day of admission (ie, the date of admission was the same as the procedure date). These patients were considered the "stable angina" cohort and were the main focus of this analysis. These criteria were used to allow correct classification of stable, elective cases into the COURAGE-like patient group, and avoid misclassification of unstable angina patients undergoing PCI as an inpatient. All other PCI patients were placed in an "other indications" cohort. 
Statistical Analysis
Results
From January 2006 to June, 2009, a total of 26 388 patients underwent PCI in NNE. Of these, 4680 (17.7%) patients underwent PCI for stable angina and 18 667 (82.3%) for other indications. Comparison between patients undergoing a PCI in the quarter immediately before publication of COURAGE (January to March 2007) versus 6 months after publication (October to December 2007) showed similar patient characteristics with overall distributions of age, sex, comorbid conditions, and cardiac history in both groups (Table) . Patients treated after the publication of COURAGE were more likely to receive complete revascularization and less likely to receive a drug-eluting stent. There were no in-hospital deaths or emergency CABG surgeries in this quarterly comparison.
Over the study period, there was a statistically significant decrease in the overall volume of PCI ( Figure 1A 
Discussion
Our study shows that after publication of the COURAGE trial, there was a significant decrease in the number of patients undergoing PCI for stable angina in northern New England. This decline was much larger than for patients undergoing PCI for other indications. In fact, compared with PCI volumes in the 2 quarters immediately before release of the COURAGE (Q4 2006 to Q1 2007), there was essentially no change in the PCI numbers for other indications but a significant decrease in PCI volumes for the stable angina population after COURAGE. This temporal change in practice suggests there was an immediate and sustained impact of COURAGE on the practice of PCI in northern New England.
Since the release of COURAGE results, routine PCI for patients with stable angina as the initial treatment strategy has been intensely debated. [15] [16] [17] [18] [19] [20] The impact of the trends described from our regional registry is directly proportional to existing practice patterns within other regions. According to the authors of COURAGE, in contemporary practice, PCI for stable angina represents 85% of all PCI. More recently data from the National Cardiovascular Data Registry (NCDR) showed that approximately only one-third of all PCI is performed in patients with stable angina or CAD. 21 Our results show that in northern New England on average only 17.7% of all PCI are performed for stable angina. Despite stable angina representing a minority of all PCI in NNE, there was still a noticeable decrease in PCI volumes within this patient group. It is conceivable that this impact would be more pronounced in regions where PCI for stable angina is more prevalent.
Although other factors may have affected PCI volumes during this time period, the sharp drop in elective PCI came shortly after COURAGE presentation and suggests a real effect of clinical trial results on physician behaviors. A possible explanation for our observations may relate to the timing of publication of COURAGE. Data from European registries linking DES with fatal stent thrombosis was released a few months prior [22] [23] [24] and COURAGE may have accentuated fears related to DES and PCI therapy. Before the publication of COURAGE, we did start to note an initial decline in total PCI volumes in the NNE population in Quarters 3 and 4 2006, which temporally was associated with the presentations focusing on DES and stent thrombosis at the World Congress of Cardiology meeting in August 2006. As total PCI volumes were dropping in our late 2006 regional experience, there was a parallel decrease in the use of DES and increase in the use of BMS (Figure 3, PϽ0.01) . This supports the supposition that this early change in PCI volumes probably was a response to concerns about adverse events associated with the use of DES.
Another possible explanation for our trends may relate to changes in the referral and treatment threshold after COUR-AGE. Although we are unable to trend overall diagnostic catheterization referral and medication use patterns, it is possible that after COURAGE, there was a higher threshold to refer patients with stable angina for cardiac catheterization and subsequent PCI, with more emphasis on candidacy for other therapies such as medical therapy or surgical revascularization.
A small study of 332 patients at a large, single center also showed immediate impact of the COURAGE trial on the treatment of patients with stable angina. Authors reported a decrease in catheterization referral volume, increase in medication use, and the use of medical therapy rather than revascularization among patients with stable angina. 25 To our knowledge, ours is the first large, regional study to report on changes in the use of PCI for the treatment of stable angina after publication of the COURAGE trial.
Limitations
We have taken a very conservative approach to defining our stable angina cohort by requiring that their procedure be performed on the day of admission as an elective case with the indication of stable angina. This restriction should limit misrepresentation of a broader patient population; however, it is possible that some patients with more unstable syndromes such as patients admitted to the hospital for a chest pain syndrome with negative cardiac enzymes may have been misclassified. Our registry did not permit accurate identification of this patient population. We report on a regional experience in the northeast and thus, broader application of our results can be questioned. We urge others with access to large datasets to consider replicating our study. Ours is a PCI registry and not a registry of patients with stable angina. The true impact of COURAGE would best be described by reporting on the changes in treatment strategies for this patient population including referral for catheterization. Last, we were unable to detail medical therapy regimens before and after COURAGE. This would have allowed for a more detailed examination of changes in treatment patterns based on COURAGE.
Conclusions
In this era of increasing emphasis on evidence-based care, we found that publication of results from the COURAGE trial were temporally associated with a significant and sustained decline in the use of PCI to treat patients with stable angina. The long-term impact of this change in practice on patient outcomes remains unknown.
